Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2014133022 |
Title |
Tetrahydroimidazo[1,5-D][1,4]Oxazepine Derivative. |
Abstract |
A compound represented by general formula (I) [wherein R represents a hydrogen atom, a C1-6 alkyl group or the like; R1 represents a C1-6 alkyl group, a C1-6 alkoxy group or the like; R2 represents a. |
Applicant(s) |
Eisai R & D Management Co., Ltd |
Representative Drug(s) |
D0LI2E |
Drug Info
|
IC50 = 1.1 nM |
Click to Show More |
[1] |
2
|
D0NE0W
|
Drug Info
|
IC50 = 3.7 nM
|
[1] |
3
|
D0Q2FC
|
Drug Info
|
IC50 = 4.7 nM
|
[1] |
4
|
D0C2ZJ
|
Drug Info
|
IC50 = 10 nM
|
[1] |
5
|
D0N9IA
|
Drug Info
|
IC50 = 60 nM
|
[1] |
6
|
D0CZ6T
|
Drug Info
|
IC50 = 103.4 nM
|
[1] |
Patent ID |
WO2013066736 |
Title |
Quinoline Carboxamide and Quinoline Carbonitrile Derivatives As Mglur2-Negative Allosteric Modulators, Compositions, and Their Use. |
Abstract |
The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0K1RU |
Drug Info
|
IC50 = 5 nM |
Click to Show More |
[1] |
2
|
D09NRH
|
Drug Info
|
IC50 = 9 nM
|
[1] |
3
|
D0OT4O
|
Drug Info
|
IC50 = 12 nM
|
[1] |
4
|
D03KYL
|
Drug Info
|
IC50 = 21 nM
|
[1] |
5
|
D09JZA
|
Drug Info
|
IC50 = 21 nM
|
[1] |
6
|
D04LRT
|
Drug Info
|
IC50 = 24 nM
|
[1] |
7
|
D0E5QO
|
Drug Info
|
IC50 = 38 nM
|
[1] |
Patent ID |
WO2012068067 |
Title |
4-Substituted-3-Phenylsulfanylmethyl-Bicyclo[3.1.0]Hexane Compounds As Mglur 2/3 Antagonists. |
Abstract |
A mGlu2/3 receptor antagonist of the formula (I):, its uses, and methods for its preparation are described. |
Applicant(s) |
Eli Lilly and Company |
Representative Drug(s) |
D0SF1E |
Drug Info
|
IC50 = 12.7 nM |
Click to Show More |
[1] |
2
|
D0KV7D
|
Drug Info
|
IC50 = 15.4 nM
|
[1] |
Patent ID |
WO2012068041 |
Title |
4-Substituted-3-Benzyloxy-Bicyclo[3.1.0]Hexane Compounds As Mglur 2/3 Antagonists. |
Abstract |
A mGlu2/3 receptor antagonist of the formula: (formula), its uses, and methods for its preparation are described. |
Applicant(s) |
Eli Lilly and Company |
Representative Drug(s) |
D01VZE |
Drug Info
|
IC50 = 13.1 nM |
Click to Show More |
[1] |
2
|
D0D4OW
|
Drug Info
|
IC50 = 43.3 nM
|
[1] |
Patent ID |
WO2008119689 |
Title |
Pyridine and Pyrimidine Derivatives As Mglur2 Antagonists. |
Abstract |
The present invention relates to compounds of formula (I), a process for the manufacture thereof, their use for the preparation of medicaments for treating CNS disorders and pharmaceutical compositions containing them. Compounds of formula (I) are represented by general formula (I) wherein Q, A, B, X, Y, R 1 and R 2 are defined as in the specification. |
Applicant(s) |
F. Hoffmann-La Roche Ag |
Representative Drug(s) |
D0H2BU |
Drug Info
|
Ki = 2 nM |
Click to Show More |
[1] |
2
|
D0O9TL
|
Drug Info
|
Ki = 5.3 nM
|
[1] |
3
|
D09OQZ
|
Drug Info
|
Ki = 14.3 nM
|
[1] |
4
|
D0YZ7D
|
Drug Info
|
Ki = 15 nM
|
[1] |
5
|
D0N0FA
|
Drug Info
|
Ki = 15.6 nM
|
[1] |
Patent ID |
WO2003066623 |
Title |
Dihydrobenzodiazepin-2-One Derivatives for The Treatment of Neurological Disorders. |
Abstract |
This invention relates to dihydro-benzo [b] [1, 4] diazepin-2-one derivatives of the general formula: (Formula I); wherein R1, R2, X and Y are as defined in the specification and R3 is a six-membered aromatic heterocycle containing 1 to 3 nitrogen atoms or a pyridine-N-oxide as further defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders. |
Applicant(s) |
F. Hoffmann-La Roche Ag |
Representative Drug(s) |
D09WXH |
Drug Info
|
IC50 = 6.4 nM |
Click to Show More |
[1] |
2
|
D04VAE
|
Drug Info
|
IC50 = 34 nM
|
[1] |
Patent ID |
WO200283665 |
Title |
Dihydrobenzo[B][1,4]Diazepin-2-One Derivatives As Metabotropic Glutamate Receptor 2 (Mglur2) Antagonists. |
Applicant(s) |
F. Hoffmann-La Roche Ag |
Representative Drug(s) |
D09WXH |
Drug Info
|
IC50 = 6.4 nM |
Click to Show More |
[1] |
2
|
D04VAE
|
Drug Info
|
IC50 = 34 nM
|
[1] |
Patent ID |
WO200283652 |
Title |
Dihydrobenzo[B][1,4]Diazepin-2-Ones As Mglur2 Antagonists for Treatment of Neurological Disorders. |
Applicant(s) |
F. Hoffmann-La Roche Ag |
Representative Drug(s) |
D09WXH |
Drug Info
|
IC50 = 6.4 nM |
Click to Show More |
[1] |
2
|
D04VAE
|
Drug Info
|
IC50 = 34 nM
|
[1] |
Patent ID |
WO200129012 |
Title |
Benzodiazepine Derivatives As Metabotropic Glutamate Receptor Antagonists. |
Applicant(s) |
F. Hoffmann-La Roche Ag |
Representative Drug(s) |
D09WXH |
Drug Info
|
IC50 = 6.4 nM |
Click to Show More |
[1] |
2
|
D04VAE
|
Drug Info
|
IC50 = 34 nM
|
[1] |
Patent ID |
WO200129011 |
Title |
Benzodiazepine Derivatives As Metabotropic Glutamate Receptor Antagonists. |
Applicant(s) |
F. Hoffmann-La Roche Ag |
Representative Drug(s) |
D09WXH |
Drug Info
|
IC50 = 6.4 nM |
Click to Show More |
[1] |
2
|
D04VAE
|
Drug Info
|
IC50 = 34 nM
|
[1] |
Patent ID |
WO2012099200 |
Title |
Pyrazole Derivative. |
Abstract |
A compound represented by formula [I] [wherein R1 represents an alkyl group or the like; R2 represents a hydrogen atom or the like; the ring A represents a phenyl group or the like; R3 represents a hy. |
Applicant(s) |
Taisho Pharmaceutical Co., Ltd |
Representative Drug(s) |
D0QM1R |
Drug Info
|
IC50 = 2.7 nM |
Click to Show More |
[1] |
2
|
D02RRE
|
Drug Info
|
IC50 = 36.4 nM
|
[1] |
3
|
D0S5SK
|
Drug Info
|
IC50 < 100 nM
|
[1] |
4
|
D0HD8F
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2012020820 |
Title |
Heteroaryl-Pyrazole Derivative. |
Abstract |
A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound exerting antagonistic activity against group II metabotropic glutamate (mGlu) receptors and a pharmaceutically accepted salt of said novel compound, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, and sleep disorders. |
Applicant(s) |
Taisho Pharmaceutical Co., Ltd |
Representative Drug(s) |
D03PRA |
Drug Info
|
IC50 = 1.29 nM |
Click to Show More |
[1] |
2
|
D0K0ZX
|
Drug Info
|
IC50 = 9.06 nM
|
[1] |
3
|
D0O6QC
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2012015024 |
Title |
Ethinyl-Pyrazole Derivative. |
Abstract |
Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The. |
Applicant(s) |
Taisho Pharmaceutical Co., Ltd |
Representative Drug(s) |
D0BP6R |
Drug Info
|
IC50 = 2.72 nM |
Click to Show More |
[1] |
2
|
D0B6DN
|
Drug Info
|
IC50 = 13.8 nM
|
[1] |
3
|
D01EVT
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2007110337 |
Title |
Pyridine and Pyrimidine Derivatives As Mglur2 Antagonists. |
Abstract |
The present invention relates to compounds of formula (I), a process for the manufacture thereof, their use for the preparation of medicaments for treating CNS disorders and pharmaceutical compositions containing them: wherein A, B, X, Y, R1, R2, R3 and R4 are as defined in the description and claims. |
Applicant(s) |
F. Hoffmann-La Roche Ag |
Representative Drug(s) |
D0IY8T |
Drug Info
|
Ki = 0.7 nM |
Click to Show More |
[1] |
2
|
D0I6LO
|
Drug Info
|
Ki = 1.7 nM
|
[1] |
3
|
D0H2LD
|
Drug Info
|
Ki = 3 nM
|
[1] |
4
|
D06NZY
|
Drug Info
|
Ki = 5 nM
|
[1] |
5
|
D0Y5DN
|
Drug Info
|
Ki = 7 nM
|
[1] |
6
|
D08PHH
|
Drug Info
|
Ki = 9 nM
|
[1] |
7
|
D0KZ6Q
|
Drug Info
|
Ki = 28 nM
|
[1] |
8
|
D0RX0M
|
Drug Info
|
Ki = 28 nM
|
[1] |
9
|
D0N1CC
|
Drug Info
|
Ki = 32 nM
|
[1] |
10
|
D0IL4Z
|
Drug Info
|
Ki = 74 nM
|
[1] |
11
|
D05CBS
|
Drug Info
|
Ki = 140 nM
|
[1] |
Patent ID |
WO2013111796 |
Title |
N-Substituted Pyrazole Derivative. |
Applicant(s) |
Taisho Pharmaceutical Co., Ltd |
Representative Drug(s) |
D0V0BC |
Drug Info
|
IC50 = 1.39 nM |
Click to Show More |
[1] |
2
|
D0WP5S
|
Drug Info
|
IC50 = 4.66 nM
|
[1] |
3
|
D08JPW
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2014059111 |
Title |
Method for Increasing The oral Bioavailability of A Metabotropic Glutamate 2/3 Receptor Antagonist. |
Abstract |
A method of increasing the oral bioavailability of an mGluR 2/3 antagonist by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of the mGluR 2/3 antagonist in a suitable container and associated with printed labeling which describes the increased oral bioavailability of the medication in the container when taken with food. |
Applicant(s) |
Braincells, Inc |
Representative Drug(s) |
D0P7DA |
Drug Info
|
Ki > 1000 nM |
[1] |
Patent ID |
WO2013062680 |
Title |
Novel Compounds and Compositions Thereof for Treating Nervous System Disorders. |
Abstract |
The present invention relates to a novel compound, methods of synthesizing the compound, compositions containing the compound, and methods for using the compound or composition to treat and/or prevent diseases and/or conditions of the central and peripheral nervous system. |
Applicant(s) |
Braincells, Inc |
Representative Drug(s) |
D0P7DA |
Drug Info
|
Ki > 1000 nM |
[1] |
Patent ID |
WO2015004007 |
Title |
Ethynyl Derivatives As Metabotropic Glutamate Receptor Antagonists. |
Abstract |
The present invention relates to ethynyl derivatives of formula (I) wherein Y is N or CH; R1 is hydrogen, fluoro or chloro; and R2 is hydrogen or lower alkyl; or to a pharmaceutically acceptable acid addition salt thereof. It has now surprisingly been found that the compounds of general formula (I) are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD). |
Applicant(s) |
F. Hoffmann-La Roche Ag |
Patent ID |
WO2012052451 |
Title |
Metabotropic Glutamate Receptor Modulators. |
Abstract |
The invention relates to heterocyclic derivatives of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders wherein Y, W, R1, R2 and R3 are as defined in claim 1. |
Applicant(s) |
Merz Pharma Gmbh & Co Kgaa |